1. Academic Validation
  2. Tranylcypromine-Based LSD1 Inhibitors as Useful Agents to Reduce Viability of Schistosoma mansoni

Tranylcypromine-Based LSD1 Inhibitors as Useful Agents to Reduce Viability of Schistosoma mansoni

  • ACS Infect Dis. 2025 Aug 8;11(8):2178-2189. doi: 10.1021/acsinfecdis.5c00224.
Emanuele Fabbrizi 1 Gebremedhin Solomon Hailu 2 A Ganesan 3 Rossella Fioravanti 1 Clemens Zwergel 1 Chiara Lambona 1 Sergio Valente 1 Giulia Fianco 4 Angela Iuzzolino 4 Daniela Trisciuoglio 4 Jonatan Caroli 5 Andrea Mattevi 5 Cécile Häberli 6 Jennifer Keiser 6 Dante Rotili 7 8 Antonello Mai 1
Affiliations

Affiliations

  • 1 Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
  • 2 School of Pharmacy, Mekelle University, Mekelle 0231, Ethiopia.
  • 3 School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, U.K.
  • 4 Institute of Molecular Biology and Pathology, National Research Council (CNR), Rome 00185, Italy.
  • 5 Department of Biology and Biotechnology, University of Pavia, Via Ferrata 9, Pavia 27100, Italy.
  • 6 Swiss Tropical and Public Health Institute, University of Basel, 4002 Allschwil, Switzerland, 4001 Basel, Switzerland.
  • 7 Department of Science, Roma Tre University of Rome, Viale Guglielmo Marconi 446, 00146 Rome, Italy.
  • 8 Biostructures and Biosystems National Institute (INBB), Via dei Carpegna 19, 00165 Rome, Italy.
Abstract

Schistosoma infections remain a major public health issue mainly in tropical and subtropical regions. While Praziquantel is the primary treatment for schistosomiasis, its limitations include resistance development and poor efficacy against juvenile worms. Given the biological similarities between tumor and parasite-infected cells, LSD1 inhibitors─primarily explored as Anticancer agents─have been investigated for their antiparasitic potential.

Keywords

LSD1; S. mansoni; cytotoxicity; lysine demethylases; reduction of viability.

Figures
Products